US 9561206
Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
granted A61KA61K31/20A61K31/201
Quick answer
US patent 9561206 (Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome) held by United States of America as represented by the Secretary of the Air Force expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- United States of America as represented by the Secretary of the Air Force
- Grant date
- Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/20, A61K31/201, A61K31/202, A61P